Gene therapy using the AAV therapy, RAAV-GPE-G6PT, in knockout mice effectively normalized blood glucose, reduced glycogen accumulation in the liver and kidneys, prevented neutropenia, and improved renal function, indicating a promising treatment approach [31]. This evidence concerns the gene SLC37A4 and neutropenia.